One Pharma Drugs & Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 12-12-2024
- Paid Up Capital ₹ 0.40 M
as on 12-12-2024
- Company Age 14 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
About One Pharma Drugs & Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Ajay Mahajan, Anisha Mahajan, Dalbir Singh, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232DL2010PTC207990
- Company No.
207990
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Sep 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does One Pharma Drugs & Pharmaceuticals Private Limited offer?
One Pharma Drugs & Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Cough Syrup, Nasal Drops, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Ferrous Ascorbate Syrup, Digestive System Drugs & Medicines, Antacid Drugs, Pain Relief Drugs & Pharmaceuticals, Muscle Relaxant.
Who are the key members and board of directors at One Pharma Drugs & Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Mahajan  | Director | 08-Sep-2010 | Current |
| Anisha Mahajan | Director | 08-Sep-2010 | Current |
| Dalbir Singh | Director | 10-Jan-2012 | Current |
| Harjit Kaur | Director | 28-Oct-2011 | Current |
Financial Performance of One Pharma Drugs & Pharmaceuticals.
One Pharma Drugs & Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of One Pharma Drugs & Pharmaceuticals?
In 2017, One Pharma Drugs & Pharmaceuticals had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at One Pharma Drugs & Pharmaceuticals?
Unlock and access historical data on people associated with One Pharma Drugs & Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of One Pharma Drugs & Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped One Pharma Drugs & Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
